



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Ping Zheng,
✉ zpm321@126.com
Yilei Li,
✉ liyilei1975@163.com

[†]These authors have contributed equally to this work and share first authorship

RECEIVED 23 October 2025
ACCEPTED 28 October 2025
PUBLISHED 14 November 2025

CITATION
Liu Y, Lin T, Zhao B, Li Y and Zheng P (2025)
Correction: Correlation analysis between
plasma concentration of nilotinib and clinical
efficacy and safety in patients with chronic
myeloid leukemia: a single-center
retrospective cohort study.
Front. Pharmacol. 16:1730637.
doi: 10.3389/fphar.2025.1730637

COPYRIGHT
© 2025 Liu, Lin, Zhao, Li and Zheng. This is an
open-access article distributed under the terms
of the [Creative Commons Attribution License](#)
(CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in this
journal is cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

Correction: Correlation analysis between plasma concentration of nilotinib and clinical efficacy and safety in patients with chronic myeloid leukemia: a single-center retrospective cohort study

Ying Liu^{1†}, Taoyan Lin^{1,2†}, Boxin Zhao^{1,2}, Yilei Li^{1,2*} and Ping Zheng^{1,2*}

¹Department Pharmacy, Institute Nanfang Hospital, Organization Southern Medical University, Guangzhou, China, ²Department Clinical Pharmacy Center, Institute Nanfang Hospital, Organization Southern Medical University, Guangzhou, China

KEYWORDS

nilotinib, chronic myeloid leukemia, plasma concentration, TDM, efficacy, safety

A Correction on

Correlation analysis between plasma concentration of nilotinib and clinical efficacy and safety in patients with chronic myeloid leukemia: a single-center retrospective cohort study

by Liu Y, Lin T, Zhao B, Li Y and Zheng P (2025). *Front. Pharmacol.* 16:1676800. doi: 10.3389/fphar.2025.1676800

The **funding statement** was erroneously written as “This study is supported by the Guangdong Pharmaceutical Association (Nos. 2023JZ04, 2024A02036, 2025HJB01006, 2025A02036) to YL.” This has now been corrected to the following: “This study is supported by the Guangdong Pharmaceutical Association (No. 2024A02036 and 2025HJB01006 to YTL; No. 2023JZ04 and 2025A02036 to PZ).”

The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.